Q-omics provides the consensus-scored POTEI profile across patient tissues and cancer cell-line models. POTEI expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, POTEI is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, POTEI protein abundance shows 26,654 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BRCA, HNSC, and PDAC as cancer lineages where POTEI shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEI — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEI survival associations across molecular data types. POTEI RNA expression shows survival associations in the most cancer types (19), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEI RNA expression–survival associations across cancer types. High POTEI expression shows unfavorable associations in STAD, LGG, LIHC and DLBC, but favorable associations in BRCA and READ. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for POTEI RNA expression.
This table summarizes POTEI tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POTEI. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEI shows lower tumor expression in THCA and higher tumor expression in HNSC, BRCA, PRAD, READ and LIHC. The HNSC box plot shows higher POTEI RNA expression in tumor versus normal tissue (log2 FC = +0.011, t-test p = .005).
This table shows molecular features associated with POTEI in patient tissues and cancer cell lines. In patient samples, POTEI shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEI RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
